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Abstract: Ischemic heart disease (IHD) is the leading cause of death and disability worldwide. The major pathological consequences of 
IHD arise from the detrimental effects of acute ischemia-reperfusion injury (IRI) on the myocardium. Therefore, in order to improve 
clinical outcomes in patients with IHD, novel therapeutic strategies are required to protect the myocardium from acute IRI and preserve 
cardiac function (cardioprotection). In this regard, endogenous cardioprotective strategies such as ischemic preconditioning (IPC), 
ischemic postconditioning (IPost) and remote ischemic conditioning (RIC) may provide novel approaches for protecting the heart in 
clinical settings in which the patient experiences acute myocardial IRI. In this review article, we provide an overview of these endoge-
nous cardioprotective strategies with respect to the pre-clinical experimental literature, exploring their major characteristics and underly-
ing signaling mechanisms. The application of these therapeutic strategies in the clinical setting for potential patient benefit is reviewed in 
another article in this special issue. 
Keywords: Ischemic preconditioning, ischemic postconditioning, remote ischemic conditioning, cardioprotection, ischemia-reperfusion 
injury. 
1. INTRODUCTION 
 “…..we could exploit ischemia to protect the heart from 
ischemic injury.” Murry et al 1986 [1]. 
 Ischemic heart disease (IHD) is the leading cause of death and 
disability worldwide. Despite optimal therapy, the morbidity and 
mortality from IHD remain significant. As such, novel therapeutic 
strategies are required to protect the heart from the detrimental 
effects of acute ischemia-reperfusion injury (IRI), in order to reduce 
myocardial injury, preserve cardiac function and improve clinical 
outcomes in patients with IHD. 
 Over 25 years ago, Murry and co-workers [1] first introduced 
the possibility of harnessing the heart’s own ability to protect itself 
from acute lethal IRI by preconditioning it with brief non-lethal 
episodes of ischemia and reperfusion, an endogenous cardioprotec-
tive phenomenon which was termed ischemic preconditioning 
(IPC). In that landmark experimental study, four-5 min cycles of 
alternating left anterior descending (LAD) coronary artery occlu-
sion and reflow applied immediately prior to a 90 min LAD occlu-
sion and 3 day reperfusion period, reduced myocardial infarct (MI) 
size in the canine heart to 25% of that observed in untreated control 
hearts. The inspiration for undertaking this seminal study was based 
on the results of experimental studies which had unexpectedly 
found that repeated bouts of myocardial ischemia and reperfusion 
did not cause a cumulative detrimental effect on myocardial ATP 
content, cell death and myocardial function [2, 3]. 
  IPC remains one of the most powerful therapeutic strategies for 
reducing MI size and has become a ubiquitous phenomenon, pro-
tecting every species it has been tested in including man. Despite 
intensive investigation and the publication of nearly 7,000 studies 
on PubMed, the on-going challenge has been to elucidate the 
mechanistic pathways underlying IPC. Over the years the concept 
of IPC has evolved to include ischemic postconditioning (IPost) and 
remote ischemic conditioning (RIC), therapeutic strategies which 
can be collectively termed ischemic conditioning. These advances 
have greatly facilitated the translation of ischemic conditioning into  
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the clinical settings of acute IRI. The clinical application of 
ischemic conditioning is discussed in another article in this special 
issue. In this review article, an overview will be provided of these 3 
forms of ischemic conditioning, with respect to the pre-clinical 
experimental literature exploring their major characteristics and 
underlying signalling mechanisms. It would be impossible for a 
single review article to provide a comprehensive account of these 
individual endogenous cardioprotective phenomena and for this the 
reader is referred to the following review articles [4-7]. 
2. HOW THE CONCEPT OF IPC HAS EVOLVED OVER 
THE YEARS 
 The concept of IPC has evolved over the years since its initial 
discovery in 1986 to now include remote ischemic conditioning 
(RIC) and ischemic postconditioning (IPost). The first major devel-
opment took place in 1993 by Przyklenk et al [8] who found that 
applying an IPC protocol in one coronary vascular territory could 
actually protect the myocardium in a different coronary vascular 
territory from a subsequent lethal episode of acute myocardial IRI. 
In this landmark experimental study undertaken in canine hearts, 
IPC in the circumflex artery (four-5 min alternating cycles of occlu-
sion and reflow), immediately prior to a 60 min LAD occlusion and 
3 day reperfusion period, reduced MI size to 38% of that observed 
in untreated control hearts [8]. The idea of undertaking this experi-
ment was based on the findings of a study by the same research 
group in isolated rat hearts, in which it was demonstrated that MI 
size expressed as a percentage of the area-at-risk actually increased 
in IPC-treated hearts whereas in control hearts, MI size did not 
increase [9]. This led the authors to propose that IPC might some-
how produce a diffusible protective factor in remote non-ischemic 
myocardium [9]. This intramyocardial preconditioning effect be-
tween two different but adjacent coronary vascular beds was further 
developed in an experimental study in 1996, demonstrating that the 
IPC stimulus could actually be applied to an organ away from the 
heart. Gho et al [10] demonstrated that applying 15 min of anterior 
mesenteric artery occlusion followed by 15 min reflow to induce a 
brief period of episode of intestinal ischemia and reperfusion im-
mediately prior to 60 min coronary artery occlusion and 180 min 
reflow reduced subsequent myocardial infarct size by 28%. This 
phenomenon has been termed remote ischemic preconditioning 
(RIPC), and subsequent studies have demonstrated that the precon-
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ditioning stimulus can be applied in any organ or tissue to protect 
any other organ or tissue from a sustained lethal episode of acute 
IRI- termed inter-organ preconditioning [7]. Crucially, the remote 
preconditioning stimulus has been shown to be effective if applied 
prior to (RIPC) [10], after the onset of (remote ischemic precondi-
tioning) [11] and even at the onset of myocardial reperfusion (re-
mote ischemic postconditioning) [12]. Furthermore, the ability to 
remotely precondition the upper or lower limb to protect the heart 
from acute IRI has greatly facilitated the translation of remote 
ischemic preconditioning into the clinical setting of cardiac surgery, 
acute myocardial infarction and coronary angioplasty [13-16].  
 The next major development occurred soon after the first de-
scription of RIPC, with the discovery in 1993 by Kuzuya et al [17] 
that IPC actually induced two distinct windows of cardioprotection. 
These authors demonstrated in the canine heart that following a 
standard IPC stimulus, MI size reduction was observed immediately 
but was lost 6 or 12 hours later and then re-appeared again at 24 
hours and lasted until 72 hours [17]. This delayed effect of IPC has 
been termed the second window of protection or delayed or late 
preconditioning [18].  
 In 2003, Zhao et al [19] found that by simply interrupting myo-
cardial reperfusion with several short-lived episodes of myocardial 
ischemia could reduce MI size to a level comparable to IPC. These 
authors demonstrated in canine hearts that following a 60 min of 
coronary artery occlusion, by allowing reflow for 30 seconds and 
then re-occluding the coronary artery for 30 seconds a cycle which 
was repeated a total of 3 times, reduced MI size when compared to 
hearts which received uninterrupted reperfusion [19]. This phe-
nomenon, which has been termed ischemic postconditioning (IPost) 
provides a cardioprotective therapeutic strategy which can be ap-
plied at the onset of myocardial reperfusion, thereby allowing its 
rapid translation into the clinical setting in patients presenting with 
an acute myocardial infarction [20] and in patients undergoing car-
diac surgery [21]. The elucidation of the mechanisms underlying 
these different forms of ischemic conditioning has identified novel 
targets for cardioprotection amenable to pharmacological manipula-
tion (so-called pharmacological conditioning). 
3. ISCHEMIC PRECONDITIONING 
3.1. The IPC Stimulus 
 In the original study by Murry et al [1], four-5 min cycles of 
myocardial ischemia and reperfusion were chosen to precondition 
the canine heart against myocardial infarction. This treatment pro-
tocol was chosen by the authors as longer periods of myocardial 
ischemia (such as 10 or 15 min) resulted in arrhythmias and in-
creased mortality [1]. The stated reason for using four cycles was to 
increase the formation and wash-out of ischemic catabolites [1]. 
The 5 min reperfusion period was chosen to be long enough to 
wash-out lactate and re-accumulate high-energy phosphates [1]. A 
wide variety of stimuli have been shown to induce a precondition-
ing-like effect in terms of cardioprotection such as heat stress, hy-
pothermia, exercise, pacing, myocardial stretch and so forth. 
 A standard IPC stimulus induces 2 phases of cardioprotection: 
the first phase (termed classical preconditioning or the first window 
of protection) begins immediately following the IPC stimulus and 
lasts for 2-3 hours, after which the cardioprotective effect wanes 
and disappears, and a second phase (termed delayed or late precon-
ditioning or the second window of cardioprotection) re-appearing 
12-24 hours later and lasting up to 72 hours [18].  
3.2. The Signaling Pathways Underlying IPC 
 The intracellular signalling pathways underlying ischemic con-
ditioning in the heart are numerous and remarkably complex and as 
such, they cannot be comprehensively reviewed in a single article. 
For IPC, the current paradigm suggests that the cardiomyocyte 
generates autacoids (such as adenosine, bradykinin, endothelin, 
opioids) in response to the IPC stimulus which bind to their respec-
tive G-protein coupled receptors and activate a number of signalling 
pathways, many of which appear to converge on the mitochondria 
(see (Fig. 1) for a simplified overview). In IPC, the signal transduc-
tion pathway can be conceptually classified into triggers (these are 
components of the signaling pathway which mainly act before the 
index ischemic episode and activate downstream signaling media-
tors) or mediators and end-effectors (these are components of the 
signaling pathway which act during the index ischemic episode or 
at the time of reperfusion and mediate the protective effect). How-
ever, this separation is not rigid as certain signaling components 
have been demonstrated to act as both triggers and media-
tors/effectors.  
3.2.1. Triggers of IPC 
 In 1991, Liu et al [22] first implicated the adenosine A1 recep-
tor as a trigger of IPC, by demonstrating that it could be blocked by 
the non-specific adenosine receptor blocker, 8-sulfophenyl-
theophylline (8-SPT), and that the intracoronary administration of 
either adenosine or an adenosine A1 receptor agonist could reduce 
MI size. These important findings demonstrated that IPC was a 
receptor-mediated phenomenon and suggested that the infarct-
limiting effects of IPC could be mimicked by a pharmacological 
agent [22]. Other GPCR ligands have been implicated as triggers of 
IPC such as bradykinin [23, 24], opioids [25], acetylcholine [26], 
catecholamines [27], angiotensin II [28], and endothelin-1 [29]. The 
IPC triggers are highly redundant with multiple cycles of IPC able 
to overcome the effect of antagonism at a single receptor [24]. The 
simultaneous activation of these GPCRs during the IPC stimulus 
suggested that the cardioprotective signal probably converges on a 
single downstream mediator, protein kinase C (PKC), which medi-
ates the memory effect of IPC. Other triggers of IPC, which are 
dealt with in later sections, include the MitoKATP channel, reactive 
oxygen species (ROS) and nitric oxide. 
3.2.2. Mediators of IPC 
 The downstream mediators of IPC are mainly protein kinases 
such as PKC, tyrosine kinase, Akt, and the mitogen activated pro-
tein kinases (MAPK) which are activated by the triggers of IPC. 
Experimental studies by Ytrehus et al in 1994 [30] showed that IPC 
could be blocked a non-specific antagonist of PKC and reproduced 
by PKC analogues. Although there are some differences with spe-
cies, IPC has been reported to activate the PKC-? isoform as a me-
diator of cardioprotection, whereas it has shown to inhibit the acti-
vation of the PKC-? isoform, which has been reported to have det-
rimental effects in the setting of IRI. It has been suggested that the 
PKC-? isoform may play a key role in the mitochondria. In 1996, 
Maulik et al [31] were the first to demonstrate that genistein, a tyro-
sine kinase antagonist could block IPC in rat hearts. Receptor tyro-
sine kinases may act as IPC triggers by activating PKC and cytoso-
lic tyrosine kinases may act as IPC mediators by acting either 
downstream or in parallel with PKC [32].  
 Experimental studies have implicated signaling through the 
phosphatidyl inositol 3-OH kinase (PI3K)-Akt cascade during the 
preconditioning phase before the index ischemic episode [33] and at 
the time of myocardial reperfusion as part of the Reperfusion Injury 
Salvage Kinase (RISK) pathway [34]. In IPC Tong and colleagues 
[33] were the first to demonstrate that IPC activates the PI3K-Akt 
kinase cascade prior to the index ischaemic episode, and that the 
PI3K inhibitor Wortmannin could abolish IPC. We showed that IPC 
could activate Akt at the time of myocardial reperfusion and that 
pharmacologically inhibiting PI3K at this time could block IPC 
protection, suggesting that IPC could modify signalling events hap-
pening at the time of myocardial reperfusion [34]. Solenkova et al 
[35] extended these findings by demonstrating that the IPC induced 
activation of Akt could be abrogated by 8-SPT (an adenosine recep-
tor antagonist), suggesting that endogenous adenosine activated Akt 
in preconditioned hearts.  
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 Whether Erk1/2 MAPK contributes to cardio-protection associ-
ated with classical preconditioning is unclear with studies demon-
strating that it is activated prior to the index ischaemic period [36-
39], but only some of these studies show these MAPK’s contribut-
ing to IPC-induced protection [36, 37]. In contrast there are studies 
reporting no change in Erk1/2 activity in the setting of IPC [40, 41]. 
A study suggests that diazoxide-induced mitochondrial ROS release 
may activate Erk1/2 [42]. This is interesting given the findings of 
Baines and colleagues demonstrating that PKC-? modules can form 
complexes with Erk1/2-BAD, p38 and JNK at the mitochondria 
[43]. In this scenario, PKC-? appeared to phosphorylate both Erk1/2 
and p38 but down-regulate JNK [43]. Erk1/2 can mediate cellular 
protection by phosphorylating recruiting several anti-apoptotic 
mechanisms. 
 The role of p38 MAPK in the setting of cardioprotection has 
been surrounded by controversy and has been the topic of several 
reviews [44, 45]. There is general agreement that ischemia-
reperfusion activates p38 MAPK [46], but the studies investigating 
the role of p38 MAPK in cardioprotection have attracted much 
controversy. Experimental Studies suggest that IPC can activate 
[47-49] or reduce [39, 50, 51] p38 MAPK during the sustained 
ischemic episode. The generally accepted view is that IPC tran-
siently activates p38 MAPK during the preconditioning phase [52-
54], and reduces the p38 MAPK activation that occurs during the 
sustained ischemic phase [50, 54-56]. Studies have suggested that 
the p38?-isoform may mediate cell death and the p38?-isoform 
may contribute to cell survival [57]. In line with this, studies have 
suggested that it is the p38? isoform which is increased during 
ischemia [39, 52], and that hypoxic preconditioning protects myo-
cytes by reducing the activation of this isoform during hypoxia 
[39]. Conversely, Schulz and co-workers [58] found p38? MAPK 
activity to be increased in preconditioned swine hearts. 
 Experimental studies have demonstrated JNK activation in the 
setting of ischemia-reperfusion [40, 46, 52, 59]. The role of JNK in 
the setting of IPC has been controversial with studies, suggesting 
both a protective and detrimental aspect to JNK activation. Studies 
have demonstrated JNK activation in response to a preconditioning 
stimulus [40, 52, 60, 61] and that JNK mediates the protective ef-
fect of IPC [53]. Other reports have found JNK activation in re-
sponse to a preconditioning stimulus but have failed to find it con-
tributing to protection [62]. Yet other studies have failed to find 
activation of JNK in the setting of IPC [63]. Unfortunately, a re-
cently published study examining the effect of JNK1/2 transgenic 
knock-outs has only served to complicate matters further [64]. In 
this study transgenic JNK knockout mice were found to be pro-
tected in vivo against myocardial ischemia-reperfusion injury. 
However, transgenic mice with over-active MKK7, the MAPK 
kinase upstream of JNK1/2 also paradoxically displayed resistance 
to myocardial ischemia-reperfusion injury, as evidenced by a re-
duced infarct size [64].  
3.2.3. Effectors of IPC 
 A number of different effectors have been proposed over the 
years but most evidence has implicated mitochondria as the end-
effectors of IPC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Signaling pathways linking IPC and IPost to the mPTP. This scheme provides a simplified overview of two of the major signaling pathways im-
plicated in both IPC and IPost which link the cell-surface receptor to the mPTP. Of course many other signalling pathways have been implicated in both IPC 
and IPost but for the purposes of clarity these have not been included in this scheme. IPC and IPost are both seen to activate cell surface receptor, which then 
recruit a number of signal transduction pathways including the PI3K-Akt and MEK1/2-Erk1/2 pathways which terminate on the mitochondria with the activa-
tion of the MitoKATP channel and the inhibition of the mPTP. (Figure adapted from [150]). 
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3.3. IPC and Mitochondria 
 The initial experimental studies to implicate mitochondria in the 
signaling pathway of IPC were designed to investigate the mecha-
nism for the preserved myocardial ATP content in preconditioned 
hearts as originally proposed by Murry et al [1]. Over the years, the 
role of mitochondria in IPC has expanded them being potential 
trigger and effectors of cardioprotection. It appears that any stimu-
lus which mildly stresses mitochondrial function is capable of initi-
ating IPC. This mitochondrial stress then sets into place, through 
the activation of various pro-survival signaling pathways, a mito-
chondrial phenotype which is protected against a sustained lethal 
insult of IRI. 
3.4. IPC and Myocardial Energy Production 
 In the initial IPC studies undertaken by Murry et al In 1990 [1, 
65] first proposed that IPC may protect the heart by reducing myo-
cardial energy demand during myocardial ischemia thereby pre-
venting cell death by preserving myocardial ATP content and/or 
reducing catabolite accumulation. This proposal has been supported 
by a number of experimental studies reporting preserved mitochon-
drial function and maintained levels of high-energy phosphates 
[66]. The opening of the MitoKATP channel has been demonstrated 
to increase ATP synthesis [67], preserve mitochondrial energy pro-
duction [68], decrease ATP hydrolysis [69] and improve energy 
transfer at reperfusion [69].  
3.5. IPC and pH 
 During a sustained lethal episode of myocardial ischemia, the 
reduction in oxygen favors anaerobic glycolysis leading to ATP 
hydrolysis and the accumulation of lactic acid and a fall in the in-
tracellular pH to 6.0. The increase in intracellular H+ activates the 
Na
+
-H
+
 exchanger which extrudes H
+
 ions in exchange for Na
+
 ions 
resulting in intracellular Na
+
 which in turn causes the Na
+
-Ca
2+
 
exchanger to work in reverse mode extruding Na
+
 ions in exchange 
for Ca
2+
 ions the end result of which is intracellular Ca
2+
 overload. 
On reperfusing the ischemic myocardium the wash-out of lactate 
and the re-activation of ion pumps result in the rapid restoration of 
intracellular pH to pre-ischemic physiological levels of pH 7.4. 
 In 1990, Murry et al [65] first proposed that IPC may protect 
the heart by increasing glycogen depletion and reducing the rate of 
anerobic glycolysis during myocardial ischemia. Initial experimen-
tal studies did find glycogen depletion, decreased myocardial lac-
tate, and less intracellular acidosis during myocardial ischemia in 
IPC-treated hearts [65, 70, 71], the expected result of which would 
be reduced activation of the Na
+
-H
+
 and Na
+
-Ca
2+ 
exchangers and 
less intracellular Ca
2+
 accumulation [72]. However, subsequent 
experimental studies have dissociated both glycogen depletion, 
decreased lactate accumulation and less intracellular acidosis with 
IPC cardioprotection [73, 74].  
 Interestingly, the rapid restoration of intracellular physiological 
pH at the onset of myocardial reperfusion did not appear to be af-
fected by IPC [75], a finding which differs from IPost, which has 
been shown to delay the restoration of intracellular physiological 
pH within the heart, as a cardioprotective mechanism linked to 
inhibition of mPTP opening [76-78]. 
3.6. IPC and Calcium 
 Intracellular and mitochondrial calcium overload during myo-
cardial ischemia and reperfusion can cause cardiomyocyte death by 
a number of different mechanisms including mPTP opening and 
cardiomyocyte hypercontracture [79, 80]. IPC has been reported to 
protect the heart by reducing intracellular calcium and mitochon-
drial calcium accumulation. The underlying mechanism for this 
beneficial effect of IPC on calcium handling is unclear, and has 
been attributed to opening of the sarcolemmal KATP channel (with 
action potential duration shortening) [81], opening of the MitoKATP 
channel (with partial mitochondrial membrane depolarization and 
less mitochondrial calcium accumulation) [82-90], and reduced 
intracellular acidosis during myocardial ischemia (see previous 
section) [72].  
3.7. IPC and ROS 
 Reactive oxygen species (ROS) appear to play a dual role in the 
setting of IPC. On the one hand, the production of mitochondrial 
ROS (such as superoxide anion, hydrogen peroxide and hydroxyl 
radical) from the re-energization of the mitochondrial electron 
transport chain in the first few minutes of myocardial reperfusion 
mediates cardiomyocyte death by inducing mitochondrial perme-
ability transition pore (mPTP) opening and causing cell membrane 
damage by lipid peroxidation. On the other hand the generation of 
small amounts of signaling ROS prior to the index episode of myo-
cardial ischemia in response to a standard IPC stimulus is also re-
quired to mediate cardioprotection through the activation of pro-
survival protein kinases such as PKC [91], Erk1/2 [42], and p38 
MAPK [92]. 
3.7.1. IPC Attenuates Mitochondrial Production of ROS at Reper-
fusion 
 In 1994, Tosaki et al [28] first reported that IPC attenuated the 
production of ROS (detected indirectly by levels of malondialde-
hyde) at the onset of myocardial reperfusion in isolated perfused rat 
hearts. Using Lucigenin-enhanced chemiluminescence to directly 
measure levels of ROS in the isolated perfused rat heart, Crestan-
ello et al [93, 94] found that IPC generated a burst of ROS immedi-
ately following the IPC stimulus and decreased the production of 
ROS in the first 4 min of myocardial reperfusion when compared to 
control hearts. These findings have been confirmed in a number of 
subsequent experimental studies [95-99]. However, the actual 
mechanism through which IPC attenuates mitochondrial production 
of ROS at the onset of myocardial reperfusion remains unclear. It 
has been suggested that IPC may prevent mitochondrial respiratory 
impairment during myocardial ischemia thereby resulting in less 
mitochondrial ROS production at time of myocardial reperfusion. 
Another hypothesis is that IPC somehow prevents the following 
process: during myocardial ischemia, outer mitochondrial mem-
brane permeabilization allows the release of mitochondrial cyto-
chrome C, the effect of which is increased mitochondrial ROS pro-
duction [100].  
 Whether IPC can affect ROS production during myocardial 
ischemia is unclear. Experimental studies have demonstrated that 
minimal amounts of ROS were produced during myocardial ische-
mia and IPC had no effect on this [94, 95], whereas one experimen-
tal study has reported that IPC reduced the production of ROS in 
the last 10 min of myocardial ischemia in the isolated guinea pig 
heart [101]. In the latter study it was suggested that the ROS gener-
ated in the terminal phase of ischemia may somehow prime the 
heart for injury during myocardial reperfusion [101]. 
3.7.2. IPC Generates Signaling ROS Prior to Myocardial Ische-
mia 
 When present in low concentrations, reactive oxygen species 
(ROS), can modify cellular activities and participate in intracellular 
signalling [102]. In 1988, Murry et al [103] first demonstrated that 
antioxidants could abolish the protective effect of IPC, implicating 
for the first time a potential role for signalling ROS as a mediator of 
IPC, a finding which was later confirmed by several subsequent 
experimental studies [91, 104, 105]. In 1996, Crestanello et al [94] 
demonstrated that IPC generated a burst of ROS, a finding which 
has been confirmed in several studies [101, 106]. In 1997, Tritto et 
al [107] were the first to demonstrate directly that a low dose of 
ROS could mimic IPC-induced protection. A year later, Vanden 
Hoek et al [106] demonstrated using chick neonatal cardiomyocytes 
that the source of the preconditioning signaling ROS (mainly H2O2) 
was complex III of the mitochondrial electron transport chain. The 
mechanism through which IPC generates a burst of mitochondrial 
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signalling ROS has been attributed to the opening of the mitochon-
drial ATP-sensitive potassium (MitoKATP) channel (see the next 
section).  
3.8. IPC and the Mitochondrial KATP Channel 
 The role of the KATP channel in IPC has had an interesting and 
often controversial history. In 1983, Noma [108] first identified a 
sarcolemmal ATP-sensitive potassium (KATP) channel in isolated 
guinea pig cardiomyocytes, the opening of which in response to 
hypoxia or ischemia could protect the heart against IRI by shorten-
ing the action potential duration thereby reducing intracellular Ca
2+
 
loading. In 1992, Gross et al [109, 110] were the first to implicate 
the sarcolemmal KATP channel as a mediator of IPC, by demonstrat-
ing that IPC cardioprotection could be abolished by the sarcolem-
mal KATP channel blockers glibenclamide or 5-hydroxydecanoic 
acid (5-HD). Mice lacking the Kir6.2 component of the sarcolem-
mal KATP channel blockers have been reported to be resistant to IPC 
[111].  
 Following the discovery in 1991 of a KATP channel in the inner 
mitochondrial membrane [112], Garlid et al in 1997 [113] and Liu 
et al in 2008 [114] demonstrated a role for the MitoKATP channel as 
a trigger of IPC. The current paradigm suggests that the opening of 
the MitoKATP channel in response to the IPC stimulus is required to 
generate the mitochondrial signalling ROS required for the activa-
tion of downstream mediators of IPC cardioprotection such as PKC 
[115-119]. The mechanism through which MitoKATP channel acti-
vation generates ROS is unclear but the current proposition is that 
the opening of the mitochondrial KATP channel causes K
+
 influx 
into the mitochondrial matrix coupled with H
+
 efflux out of the 
mitochondria. The increase in matrix pH is accompanied by the 
influx of anions such as Pi, but because of the relatively low cytoso-
lic concentration of Pi, the net effect of K
+
 influx is matrix alkaniza-
tion, which in turn increases mitochondrial ROS production from 
complex I [120-122].  
 However, the role of the MitoKATP channel as a trigger of IPC 
cardioprotection has been surrounded by controversy due to two 
main factors: (i) much of the evidence supporting the role of this 
channel in IPC is based upon the use of pharmacological activator 
and inhibitors of the MitoKATP channel such as diazoxide and 5-
HD, respectively, agents which has been reported to have non-
specific effects on mitochondrial function [123]; and (ii) although 
the molecular structure of the sarcolemmal KATP channel is known 
to consist of an octomeric complex containing four Kir6.2 (an in-
wardly-rectifying K
+
 channel) subunits and four SUR2 (sulphony-
lurea receptor) subunits [124, 125], the molecular composition of 
the MitoKATP channel remains unknown. The situation has been 
further complicated with the discovery of a Ca
2+
-activated K
+
 chan-
nel in the inner mitochondrial membrane that can mediate protec-
tion against IRI [126]. 
3.9. IPC and Nitric Oxide 
 Whether the signalling molecule nitric oxide (NO) is a trigger 
for classical IPC was initially controversial [127-130]. However, in 
the current paradigm for IPC signaling, NO is a critical mediator in 
the IPC signalling pathways. The evidence for NO and iNOS in the 
setting of delayed IPC or SWOP is more persuasive [131, 132].  
3.10. IPC and the mPTP 
 The mPTP is a non-selective channel of the inner mitochondrial 
membrane which forms and opens in the first few minutes of myo-
cardial reperfusion in response to calcium, oxidative stress, phos-
phate and ADP [133]. Its opening collapses the mitochondrial 
membrane potential, halting mitochondrial oxidative phosphoryla-
tion resulting in ATP depletion and cell death. Furthermore, its 
opening allows water and solutes to equilibriate with the mitochon-
drial matrix leading to mitochondrial swelling and rupture of the 
outer mitochondrial membrane and the translocation of pro-
apoptotic factors such as cytochrome C into the cytosol inducing 
apoptosis. Preventing its opening at the time of myocardial reperfu-
sion is a critical target for cardioprotection. In this regard, 
Crompton’s research laboratory made the crucial discovery that the 
opening of the mPTP induced by calcium, phosphate and oxidative 
stress could be pharmacologically inhibited by the immunosuppres-
sant drug, cyclosporine-A (CsA), which targets cyclophilin D, regu-
latory component of the mPTP [134-136]. Since then we and others 
have demonstrated that pharmacologically inhibiting mPTP open-
ing at the onset of reperfusion can reduce MI size [137-139], a 
therapeutic strategy which has been applied in the clinical setting 
[140]. Importantly, mice deficient in cyclophilin-D sustained 
smaller MI [135, 136] and cerebral infarcts [141], underscoring the 
importance of the mPTP as a mediator of IRI in both the heart and 
brain. 
 The first study to suggest that the mPTP may be a potential 
target for calcium-induced preconditioning protection was by Ash-
raf’s group [142] in 2001, although no direct experimental evidence 
was provided to support this proposition. A year later, we postu-
lated and demonstrated for the first time that IPC elicited its cardio-
protective effect by targeting and inhibiting the opening of the 
mPTP [138]. We found that the preconditioning mimetic, diazoxide 
was able to reduce calcium-induced mPTP opening (measured by 
the loss of mitochondrial calcein) in adult rat cardiac mitochondria 
[138], suggesting a link between the MitoKATP channel and mPTP 
inhibition. Subsequent studies have confirmed mPTP inhibition in 
several different settings of preconditioning including: the precon-
ditioned perfused rat heart [143, 144]; the preconditioned adult rat 
cardiomyocyte [145, 146]; the anesthetic-preconditioned in vivo 
rabbit heart [147]; and the rat heart protected by delayed precondi-
tioning [148, 149]. The mechanism through which IPC actually 
inhibits the opening of the mPTP at the time of myocardial reperfu-
sion is currently unresolved but several mechanisms have been 
proposed and are reviewed in a recent review [150].  
 More controversially, we have suggested that a transient non-
lethal form of mPTP opening in response to the IPC protocol may 
contribute to IPC cardioprotection, by allowing the production of 
mitochondrial ROS to activate pro-survival kinases such as Akt 
[151, 152]. Recent imaging studies have reported flickering of the 
mPTP in intact cardiomyocytes under basal conditions associated 
with mitochondrial superoxide release [153].  
4. SECOND WINDOW OF PROTECTION 
 One or more brief non-lethal episodes of myocardial ischemia 
and reperfusion can precondition the myocardium to withstand a 
sustained episode of lethal ischemia-reperfusion injury (termed 
classical or early ischemic preconditioning, IPC) [1]. The precondi-
tioned state manifests immediately following the IPC stimulus and 
lasts for 1-2 hours after which it disappears [154]. In 1993, two 
research laboratories working independently of each other, made 
the intriguing discovery that the cardioprotective effect actually re-
appeared 24 hours later (termed the Second Window of Protection 
or delayed or late IPC). Yellon’s group [155] observed infarct-size 
reduction using an in vivo rabbit model 24 hours following a stan-
dard IPC stimulus, suggesting and terming this the Second Window 
of Protection (SWOP). Kuzuya and co-workers [17] demonstrated 
myocardial infarct size reduction using an in vivo canine model 
either immediately or 24 hours following a standard IPC stimulus, 
but failed to observe an infarct-limiting effect at 3 or 12 hours fol-
lowing the IPC stimulus, confirming the presence of a bi-phasic 
cardioprotective response to IPC.  
 Delayed preconditioning can be elicited by both non-
pharmacological stimuli (ischemia, heat stress, pacing and exercise) 
as well as pharmacological stimuli and can protect against myocar-
dial infarction, myocardial stunning, arrhythmias and endothelial 
dysfunction. The studies which originally described delayed IPC 
used four-5 minute cycles of myocardial ischemia and reperfusion 
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to elicit delayed ischemic preconditioning (delayed IPC) in the 
rabbit heart [155] and canine heart [17], probably because this was 
the standard protocol used for eliciting early IPC. However, it has 
been shown that a single-5 minute cycle is also sufficient to elicit 
delayed IPC [156].  
 One of the first studies describing the phenomenon of delayed 
preconditioning had demonstrated that heat stress could limit myo-
cardial infarct size 24 hours later and this beneficial cardioprotec-
tive effect was associated with increased myocardial levels of heat 
shock protein 72 KD (HSP72) [155]. However, the original experi-
mental study to link heat stress with cardioprotection was published 
several years earlier by Currie and co-workers in 1988 [157], who 
first demonstrated that subjecting a rat to whole body hyperthermia 
(15 minutes at 42ºC) improved post-ischemic ventricular function, 
reduced cardiac enzyme release in excised perfused hearts, reduced 
ultra-structural damage to mitochondrial and decreased oxidative 
stress. Subsequent studies have linked heat stress induced delayed 
preconditioning with the generation of myocardial heat shock pro-
teins and many of the mediators associated with delayed IPC. 
4.1. Underlying Mechanisms 
 Since the original description of SWOP or delayed IPC 18 years 
ago, the mechanisms underlying this endogenous cardioprotective 
phenomenon have been the subject of intense investigation (see 
(Fig. 2) for overview). Mechanistic pathways are needed in the 
SWOP (or delayed or late preconditioning) to relay the cardiopro-
tective signal with respect to time, from the initial IPC stimulus to 
the cardioprotective effect which manifests 24 hours later. The 
signal transduction pathway underlying delayed IPC requires ‘trig-
gers’ (substances generated during the IPC stimulus such as adeno-
sine, bradykinin, opioids, cytokines, nitric oxide [NO] or reactive 
oxygen species [ROS]) which recruit ‘early mediators’ (such as 
PKC, tyrosine kinase, PI3K-Akt, MEK1/2-Erk1/2, and JAK), which 
in turn activate transcription factors (such as STAT1/3, NF?B, AP-
1, Nrf2 and HIF-1?), resulting in the synthesis 12-24 hours later of 
‘distal mediators’ (such as iNOS, HSP and COX-2) which protect 
the heart against infarction by acting on ‘end-effectors’ or ‘targets’ 
(such as the mPTP or the mKATP channel). The requirement for the 
transcription and synthesis of de novo protein cardioprotective me-
diators is one of the major factors distinguishing delayed from early 
IPC and it may account for the observed absence of cardioprotec-
tion in the 3-12 hours following the IPC stimulus. Clearly, this clas-
sification is not rigidly adhered to with some triggers/media-
tors/effectors difficult to classify under one heading as they may 
overlap one or more categories.  
5. REMOTE ISCHEMIC CONDITIONING 
 “…preconditioning may be mediated by factor(s) activated, 
produced, or transported throughout the heart during brief ische-
mia/reperfusion.” Przyklenk et al 1993 [8]. 
 The disadvantages of IPC and also IPost are that they require an 
intervention being applied directly to the heart. Therefore, the abil-
ity to condition an organ or tissue away from the heart has facili-
tated the translation of RIC into the clinical setting. In 1993, Przyk-
lenk and colleagues made the intriguing discovery that inducing 
brief episodes of ischemia and reperfusion in the circumflex coro-
nary vascular territory had the capacity to reduce MI size, arising 
from the occlusion and reflow of the LAD coronary artery [8]. This 
form of intramyocardial protection was later extended to non-
cardiac organs, with the report that MI size could actually be re-
duced in the animal heart by inducing brief ischemia and reperfu-
sion in either the kidney [158] or the small intestine [159], immedi-
ately prior to the sustained coronary artery occlusion (reviewed in 
[160, 161]). The concept of RIPC has now been extended to differ-
ent organs and tissues such that it has emerged as a true strategy of 
inter-organ protection against the detrimental effects of acute 
ischemia-reperfusion injury (IRI) (see (Fig. 3) for overview). The 
discovery that RIPC could be elicited by inducing the remote 
ischemic conditioning (RIC) stimulus in the limb [162], by simply 
inflating and deflating a blood pressure cuff placed on the upper 
arm or thigh [13], has greatly facilitated the translation of RIC into 
the clinical setting.  
5.1. The Remote Ischemic Conditioning Stimulus 
 The remote ischemic conditioning (RIC) stimulus is more 
closely related to the IPC protocols in that they are most often char-
acterised by one to four cycles of brief ischemia and reperfusion 
(most often of 5-15 min duration). In the original study by 
Pryzklenk et al [8] four-5 min cycles of ischemia and reperfusion 
were applied to the heart. Interestingly, (most often of 5 min dura-
tion) whereas in the first demonstration of remote organ precondi-
tioning by Gho et al [10], only one-15 min cycle of ischemia and 
reperfusion was applied to the remote organ (in this case intestine 
and kidney). The clinical translation of RIC required the stimulus to 
be applied to an organ or tissue which could be easily accessed. In 
this regard, the discovery that the skeletal muscle of the lower limb 
could be remotely conditioned to protect the heart against IRI [162] 
has facilitated the translational process with the subsequent demon-
stration that the remote conditioning stimulus could be applied to 
the upper or lower limb of human volunteers and patients to non-
invasively protect the heart in clinical settings of IRI [13]. 
 Interestingly, the RIC protocols have not varied much with 
respect to the timing of the intervention with respect to myocardial 
ischemia and reperfusion. That is similar protocols have been used 
in spite of whether it was delivered as a RIPC, RIPerC or RIPost 
protocol. In the first description of RIPerC by Schmidt et al in 2007 
[11] four-5 min cycles of limb ischemia and reperfusion were ap-
plied after the onset of myocardial reperfusion. The term RIPost 
was first introduced by Kerendi et al in 2005 [163], although the 
one-5 min renal ischemia was applied during myocardial ischemia 
one minute prior to myocardial reperfusion. The first experimental 
study to actually begin the RIC protocol at the onset of myocardial 
reperfusion (the true definition of RIPost) was by Andreka et al in 
2009 [12], who demonstrated that applying four 5 min cycles of 
limb ischemia and reperfusion, at the inset of myocardial reperfu-
sion could reduce MI size using an in situ porcine model of IRI. 
The current paradigm of lethal myocardial reperfusion injury sug-
gests that the cardioprotective intervention needs to be applied ei-
ther prior to or at the immediate onset of myocardial reperfusion to 
be effective. However, in this RIPost study in which limb ischemia 
was initiated at the onset of myocardial reperfusion, the cardiopro-
tective factor would have only reached the heart after the limb has 
been reperfused which would have been after 5 min of myocardial 
reperfusion had elapsed [12]. This intriguing finding suggests that 
there may be an additional component of lethal myocardial reperfu-
sion injury which can be targeted, late into reperfusion. 
5.2. Potential Mechanisms Underlying RIC 
 The actual mechanism through which an episode of brief 
ischemia and reperfusion in an organ or tissue exerts protection 
against a subsequent sustained insult of ischemia-reperfusion injury 
in a remote organ or tissue is currently unclear (see (Fig. 4) for 
overview). Experimental studies suggest that many of the underly-
ing mechanistic pathways and signal transduction cascades acti-
vated within the protected organ may be similar to those recruited 
in the setting of IPC and IPost [164]. Mechanistic pathways are 
needed to relay the cardioprotective signal from the remote precon-
ditioned organ or tissue to the heart. However, once the cardiopro-
tective signal has reached the heart, similar signaling pathways 
underlying IPC and IPost are then believed to mediate the protec-
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Fig. (2). Signaling pathways underlying delayed preconditioning or SWOP. Overview of major signal transduction pathways underlying delayed ischemic 
preconditioning (IPC) or the second window of protection (SWOP): (a) On day 1, delayed IPC generates trigger factors such as adenosine (acting via adenosine 
A1 and A3 receptors), opioids (acting via ? and ? opioid receptors) and bradykinin (acting via the bradykinin B2 receptor) which activate intracellular signal-
ling pathways PIK3-Akt, Raf-MEK1/2-Erk1/2, and protein tyrosine kinase (PTK) which convey the cardioprotective signal to downstream pathways such as 
p70S6K, PKC-?-STAT-3, eNOS-NO-PKG-PKC?-MitoKATP. This results in the nuclear activation of transcription factors such as NF?B, STAT1/3, HIF-1?, 
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Nrf2, which transcribe de novo proteins (distal mediators) over the next 12-24 hours such as MnSOD, iNOS, COX-2, heat shock proteins (HSP), heme-
oxygenase-1 (HO-1), aldose reductase (AR), which then recruit cardioprotective pathways 24-48 hours later on the day of lethal insult of ischemia and reperfu-
sion injury (IRI). In response to the delayed IPC stimulus the generation of cytokines such as TNF-? (acting via the TNF-? receptors I and II), IL-?, and IL-6, 
which activate the JAK-STAT pathway also resulting in the transcription of distal mediators. At the level of the mitochondria the opening of the mitoKATP 
channel results in the release of signalling reactive oxygen species, which further activate protein kinases such as Erk1/2 and Akt. The opening sensitivity of the 
mitochondrial permeability transition pore (mPTP) is decreased by the IPC stimulus, which confers cardioprotection 24-48 hours later in response to the IRI. 
(b) On day 2-3, the activated distal mediators confer cardioprotection at the time of myocardial infarction or stunning through a variety of pathways. The nitric 
oxide generated by iNOS mediates cardioprotection by inhibiting mPTP opening. The activation of COX-2 generates prostaglandins PGE2 and PGF1? which 
then mediate cardioprotection through an unclear mechanism. MnSOD and HO-1 exert an antioxidant effect reducing detrimental ROS generated during IRI 
which may mediate cardioprotection by inhibiting mPTP opening at the time of myocardial reperfusion. The activation of AR mediates cardioprotection by 
decreasing cytotoxic lipid-derived aldehydes. The pro-survival kinases such as Erk1/2 and Akt are activated at the onset of myocardial reperfusion and confer 
cardioprotection through mPTP inhibition via GSK3? and the mKATP channel. Whether autocoids such as adenosine, bradykinin or opioids activate these 
kinases at the time of myocardial reperfusion in unknown. The activation of HSP27 and HSP70 mediate cardioprotection by beneficial effects on stablization of 
the actin cytoskeleton and calcium regulation, respectively. (Figure reproduced from [18]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Inter-organ protection against acute lethal ischemia-reperfusion injury. This cartoon depicts the evolution of remote ischemic preconditioning 
from a concept that was initially used to describe intramyocardial cardioprotection across coronary vascular territories. It was then demonstrated that brief 
ischemia and reperfusion of organs or tissue remote from the heart had the ability to protect the myocardium against acute lethal ischemia-reperfusion injury 
(see dashed black arrows). The concept has now been expanded between non-cardiac organs and tissues such that it represents a general form of inter-organ 
protection against acute lethal ischemia-reperfusion injury (solid black arrows link the remotely preconditioned organ or tissue to the protected target organ or 
tissue). (Figure reproduced from [7]). 
 
tive effect. However, the mechanistic pathway linking the remote 
organ or tissue to the heart is currently unclear although several 
mechanisms have been proposed. It is important to appreciate that 
these mechanistic pathways may interact with each other and are 
therefore not mutually exclusive. 
5.3. Evidence for a Potential Humoral Factor in RIC 
 The finding that sustained ischemia of the remote organ was 
unable to protect the heart and that a period of reperfusion of the 
remote organ was required, suggested that the reperfusion period 
may be needed to ‘washout’ a substance or humoral factor gener-
ated by the preconditioning ischemia, which was then transported to 
the heart [10, 158]. This hypothesis was further supported by a 
study reporting that blood taken from a rabbit which had been sub-
jected to simultaneous IPC of both the heart and kidney, could re-
duce a subsequent myocardial infarct size by 77% when transfused 
to an untreated rabbit [165], suggesting the transfer of one or more 
humoral cardioprotective factors. The same authors went onto dem-
onstrate that coronary effluent from an isolated rabbit heart treated 
with a standard ischemic preconditioning protocol, could reduce 
myocardial infarct size by 69% [166] and improve recovery of left 
ventricular function [167] when used to perfuse an untreated iso-
lated rabbit heart. 
 Convincing evidence in support of a humoral mechanism for 
RIPC was provided in an elegant experimental study by Konstanti-
nov et al [168]. Remote limb preconditioning of a pig that had re-
ceived a donor heart was able to reduce myocardial infarct size in 
the denervated donor heart, providing strong evidence that a hu-
moral mediator was responsible for RIPC protection, although an 
afferent sensory nerve pathway from the limb cannot be excluded 
[168]. A similar type of study was conducted by Kristiansen and 
colleagues [169] who demonstrated that hearts excised from a rat 
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that had been remote limb preconditioned experienced a smaller 
infarct size, when subjected to IRI. Other studies have investigated 
whether endogenous substances such as adenosine [170], bradyki-
nin [171], opioids [172], CGRP [173], and endocannabinoids [174], 
are released from the remote organ during the preconditioning 
ischemia and are carried to the heart in the blood stream where they 
then activate intracellular pathways of cardioprotection. Alterna-
tively, the endogenous mediator may activate afferent neural path-
ways within the remote preconditioned organ to confer cardiopro-
tection, as is the case with adenosine, bradykinin and CGRP.  
 In 1998, our laboratory was the first to implicate adenosine as a 
potential mediatory factor underlying cardioprotection in the setting 
of RIPC, demonstrating that the administration of the non-specific 
adenosine receptor antagonist, 8-sulphophenyltheophylline (8-
SPT), prior to the RIPC protocol could abolish the reduction in 
myocardial infarct size induced by a remote preconditioning stimu-
lus in the rabbit kidney [170]. In a subsequent study by Takao and 
colleagues [175], it was demonstrated that 8-SPT administered after 
the renal RIPC stimulus also had the ability to block cardioprotec-
tion suggesting that myocardial adenosine receptor binding was 
required for cardioprotection, a finding which was supported by 
their finding of elevated plasma levels of adenosine in blood sam-
pled from the carotid artery of rabbits subjected to RIPC compared 
to those treated with IPC alone [175]. 
 The involvement of opioid signaling in RIPC was first reported 
by Patel and colleagues in 2002 [172]. They demonstrated that the 
non-specific opioid receptor antagonist, naloxone, was capable of 
abolishing the myocardial infarct-limiting effects conferred by re-
mote intestinal preconditioning in the rat [172]. It has been pro-
posed that endogenous opioids generated by the preconditioning 
stimulus in the remote organ enter the blood stream where they act 
directly on the myocardium to confer cardioprotection [172], al-
though further studies are required to both investigate this proposal 
and delineate the individual contributions of the different receptor 
subtypes to RIPC.  
 Previous studies have implicated binding at the CB2 endocan-
nabinoid receptor of the endogenous cannabinoid system in protec-
tion from myocardial ischemia reperfusion injury [176]. A recent 
experimental study has implicated endogenous activation of the 
CB2 receptor in the myocardial infarct-limiting effects of remote 
intestinal preconditioning, using a pharmacological CB2 antagonist 
to abolish RIPC protection [174]. The authors proposed that endo-
cannabinoids generated by the intestinal ischemia may enter the 
blood stream and activate CB2 receptors on the myocardium, but of 
course further studies are required to test this hypothesis.  
5.4. What is the Identity of the Cardioprotective Factor in RIC 
 The possibility of a cardioprotective factor being transferred 
from the remote conditioned organ or tissue to the heart was first 
proposed in the initial RIC studies from 1993 [8] and 1996 [10], 
and yet the identity of the factor(s) involved remains unknown. 
Several experimental studies have attempted to identify the cardio-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Signaling pathways underlying remote ischemic preconditioning. The actual mechanism through which episode of brief ischemia and reperfusion 
in an organ or tissue remote from the heart protects the myocardium from acute IRI is currently unknown, although several hypotheses have been proposed and 
these are depicted in this figure: (1) The remotely preconditioned organ or tissue generates an endogenous substance such as adenosine, bradykinin or calci-
tonin gene-related peptide (CGRP), which then activates a local afferent neural pathway stimulating an efferent neural pathway, which terminates on the heart 
and mediates cardioprotection. (2) The remotely preconditioned organ or tissue generates an endogenous substance (such as adenosine, bradykinin, opioids, 
CGRP, endocannabinoids, Angiotensin I) or some other as yet unidentified humoral factor(s) which enters the blood stream and activates its respective recep-
tor in the myocardium thereby recruiting the various intracellular pathways of cardioprotection; (3) The remotely preconditioned organ or tissue provokes a 
systemic protective response which suppresses inflammation and apoptosis. (Figure reproduced from [7]). 
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protective factor(s) in remote preconditioned effluent or plasma 
using biochemical (chromatography) and mass spectrometry tech-
niques but the identity of the protective factor(s) remains elusive 
[177-180]. To summarize, these studies have suggested that the 
cardioprotective factor(s) are probably thermo-labile hydrophobic 
substances (probably peptides) between 3.5 to 8 kDa in size which 
have been demonstrated to act via the opioid receptor, PKC, and the 
PI3K-Akt pathway [177-181]. Whether the same protective fac-
tor(s) is released by different remotely conditioned organs or tissues 
is unknown as is whether the factor(s) have similar protective ef-
fects depending on the target organ or tissue. Furthermore, the in-
terplay between the cardioprotective factor(s) and the neural path-
way remains unclear. Interestingly, it has been recently shown that 
the plasma from remote limb preconditioned human volunteers 
protected rabbit cardiomyocytes from simulated IRI, suggesting 
cross-species cardioprotection [180].  
5.5. Evidence for a Potential Neural Pathway in RIC 
 One of the early studies of RIPC first provided potential evi-
dence that a neural pathway may underlie the cardioprotection elic-
ited by remote preconditioning a non-cardiac organ. Gho and col-
leagues [10] demonstrated that the reduction in myocardial infarct 
size induced by brief ischemia and reperfusion of the anterior mes-
enteric artery could be reversed in the presence of the ganglion 
blocker, hexamethonium. The hypothesis for a neural pathway was 
further developed with the proposition that endogenous substances 
such as adenosine [170], bradykinin [171], calcitonin gene-related 
peptide (CGRP) [173], released by the remote preconditioned or-
gan, stimulated afferent nerve fibres, which then relayed to efferent 
nerve fibres terminating on the myocardium to confer cardioprotec-
tion.  
 Ding and colleagues [182] have demonstrated that renal nerve 
section abolished the cardioprotective effect induced by a remote 
renal preconditioning stimulus providing strong supportive evi-
dence of a neural pathway. They then reported that during the re-
mote renal preconditioning stimulus renal afferent nerve discharge 
was increased and that this enhanced neural activity could be abro-
gated by 8-SPT [182]. Further confirmatory evidence implicating 
adenosine in a neural pathway of cardioprotection was provided by 
Liem and colleagues [183] who after confirming that the prior ad-
ministration of hexamethonium or 8-SPT abolished the myocardial 
infarct size reduction induced by brief mesenteric ischemia and 
reperfusion, demonstrated that the local administration of adenosine 
into the mesenteric vascular bed also conferred cardioprotection in 
a manner which was sensitive to hexamethonium [183]. These find-
ings suggested that brief episodes of ischemia of the small intestine 
may generate adenosine which would then activate mesenteric af-
ferent sensory nerves. However, the investigators went on to report 
that 8-SPT administered after the remote preconditioning stimulus 
was also able to inhibit cardioprotection, suggesting that adenosine 
receptor binding in the heart may also be required for protection 
[183]. 
 Schoemaker & van Heijningen [171] demonstrated that the 
reduction in myocardial infarct size elicited by brief mesenteric 
artery occlusion and reperfusion could be abolished by prior ad-
ministration of HOE140, a specific bradykinin B2 receptor antago-
nist. Interestingly, they went on to find that intra-mesenteric arterial 
administration of bradykinin was also able to confer cardioprotec-
tion in a manner which was sensitive to ganglion blockade by hex-
amethonium [171]. The authors suggested that bradykinin gener-
ated during the remote preconditioning intestinal ischemia, may 
stimulate mesenteric afferent sensory nerves which then mediate 
the cardioprotective effect [171]. These findings were confirmed in 
a subsequent study by Wolfrum and colleagues [184], who also 
observed that the activation of myocardial PKC-? by brief intestinal 
ischemia was blocked by HOE-140 and hexamethonium, suggest-
ing that PKC-? was positioned downstream of bradykinin and the 
neural pathway. 
 Several experimental studies have implicated calcitonin-gene 
related peptide (CGRP), a neurotransmitter released from capsaicin-
sensitive sensory nerves, as a potential mediator of both ischemic 
preconditioning [185] and RIPC [173, 186]. These can be summa-
rized as follows: remote intestinal preconditioning generates nitric 
oxide which stimulates capsaicin-sensitive sensory nerves in the 
intestinal vasculature, releasing CGRP into the blood-stream (where 
levels have reported to be increased by RIPC), which is then carried 
to the heart where it activates myocardial PKC-?. [185, 187]. 
5.6. Evidence for a Systemic Response in RIC 
 Several experimental studies have examined the effect of re-
mote preconditioning of an organ or tissue on the myocardial gene 
transcription profile [188, 189], and the inflammatory response 
[190], and have discovered that the inflammatory response is sup-
pressed and a favourable profile of gene transcription appears to be 
activated that is both anti-inflammatory and anti-apoptotic. The 
relevance of such a response to the cardioprotective effect elicited 
by RIPC is currently unclear and requires further investigation. 
5.7. Myocardial Mechanisms of Cardioprotection in RIC 
 Once the cardioprotective signal has been conveyed from the 
remotely preconditioned organ to the heart, intracellular signal 
transduction mechanisms are recruited within cardiomyocytes 
which are similar to those that participate in IPC and IPost [191]. 
These include the ligand binding to G-protein cell surface coupled 
receptors such as adenosine [170], bradykinin [171], opioids [172], 
angiotensin [192], and endocannabinoids [174]. The binding to 
these cell surface receptors appears to then activate intracellular 
kinases such as PKC-? [184] and other signalling components such 
as reactive oxygen species [193], nitric oxide and the mitochondrial 
KATP channel [170]. Whether RIPC also activates pro-survival 
kinases of the Reperfusion Injury Salvage Kinase (RISK) pathway 
and results in the inhibition of the mitochondrial permeability tran-
sition pore (mPTP), as in IPC and IPost, remains to be determined 
[164]. It has been recently shown that coronary effluent collected 
from IPC-treated hearts can protect naïve isolated perfused rat 
hearts when administered at the onset of myocardial reperfusion 
through the activation of the PI3K-Akt component of the RISK 
pathway [181]. 
5.8. Novel Concepts in RIC 
 Recent studies suggest that the heart can be protected from 
acute IRI by simply inducing surgical trauma elsewhere- a phe-
nomenon which has been termed remote preconditioning of trauma 
(RPCT) [194, 195]. Jones et al [195] demonstrated that an abdomi-
nal surgical incision was enough to protect the murine heart from 
MI. The mechanistic pathway underlying this cardioprotective ef-
fect appeared to be mediated through a neural pathway involving 
sensory fibres, spinal nerves and cardiac sympathetic nerves which 
via bradykinin activated myocardial intracellular mediators of car-
dioprotection such as PKC and MitoKATP channel. Somewhat 
remarkably, the cardioprotection could be recapitulated by simply 
applying capsaicin cream to stimulate the C sensory fibres in the 
skin. RPCT has recently been confirmed in a canine model of IRI 
with a surgical abdominal incision reducing subsequent MI size 
[196]. 
 A recent experimental study has suggested that the heart can be 
repeatedly remote ischemic postconditioned (RIPost) post-MI to 
elicit beneficial effects on LV remodelling [197]. Wei et al [197] 
found that repeating the RIPost stimulus either every day or every 3 
days for 28 days reduced adverse LV remodelling post-MI and 
improved survival at 84 days post-MI. Whether repeated RIPost 
every 3 days, in post-MI patients has beneficial effects on LV re-
modeling is an intriguing possibility. 
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6. ISCHEMIC POSTCONDITIONING 
 In 2003, Zhao et al [19] made the surprising observation that 
interrupting myocardial reperfusion with several short-lived epi-
sodes of myocardial ischemia was cardioprotective. These authors 
found that by applying three-30 second cycles of alternating LAD 
reperfusion and LAD occlusion at the onset of myocardial reperfu-
sion could reduce MI size by 44% in the canine heart [19]. Interest-
ingly the term ischemic “postconditioning” had first been coined in 
an earlier experimental study by Na et al in 1996 [198] in which it 
was demonstrated that intermittent reperfusion achieved by ven-
tricular ectopic beats could reduce reperfusion arrhythmias in a 
feline model of IRI. In fact, the concept of intermittent or gradual 
reperfusion as a cardioprotective strategy was first investigated in 
the 1980’s [199, 200] but it is the term IPost which has captured the 
imagination of the research field of cardioprotection.  
 The discovery of IPost as therapeutic cardioprotective strategy 
which can be applied at the onset of myocardial reperfusion has 
revitalized interest in lethal myocardial reperfusion injury as a tar-
get for cardioprotection and provided solid evidence for the exis-
tence of lethal myocardial reperfusion injury in both animal models 
and man.  
6.1. The IPost Stimulus 
 When compared to the IPC stimulus, which comprises one to 
four cycles of brief ischemia and reperfusion (most often of 5 min 
duration), the IPost stimulus is short-lived consisting of three to six 
cycles of ischemia and reperfusion (most often of 5 – 60 sec dura-
tion). In the original study by Zhao et al in 2003 [1], myocardial 
reperfusion was interrupted with three-30 sec cycles of myocardial 
ischemia. In IPC the brief episodes ischemia and reperfusion are 
required to induce a change in mitochondrial function whereas in 
IPost, it is probably the intermittent or stuttered reperfusion which 
is the most important aspect of the protocol. The IPost protocol 
varies from species to species with small animal myocardial models 
of IRI requiring 5 - 10 sec episodes of alternating ischemia and 
reperfusion whereas larger animal models and humans requiring 30 
– 60 sec IPost protocols [201]. With respect to the timing of the 
administration of the IPost protocol, the current paradigm suggests 
that it needs to be delivered in the first minute of myocardial 
reperfusion to be effective. However, a recent experimental study 
has suggested in the murine model of in situ myocardial IRI, the 
IPost protocol may be still effective even when administered up to 
45 min into myocardial reperfusion, suggesting that delayed post-
conditioning may be targeting a later component of myocardial 
reperfusion injury such as apoptosis or inflammation. 
 A number of pharmacological agents have been reported in 
experimental studies to reduce MI size when administered at the 
onset of myocardial reperfusion and have been termed pharmacol-
ogical postconditioning agents despite the fact that many of them 
were investigated prior to the concept of IPost was introduced.  
 In addition to protecting the heart from the known proponents 
of lethal myocardial reperfusion injury such as oxidative stress, 
calcium overload, inflammation, mPTP opening, IPost is known to 
recruit a number of signal transduction pathways many of which are 
similar to those utilized by IPC.  
6.2. Signaling Pathways Underlying IPost 
 The signal transduction pathways underlying IPost are both 
numerous and complex and only an overview can be given here. 
For more detailed accounts the reader is kindly directed to the fol-
lowing reviews [5, 202]. There are many similarities in the endoge-
nous signal transduction pathways underlying classical or acute IPC 
and IPost in the cardiomyocyte. The obvious difference between the 
two, however, is the need to have a mechanism in place to mediate 
the ‘memory’ effect of IPC to sustain the cardioprotective effect for 
the first 2-3 hours. In contrast, the cardioprotective effect of IPost is 
manifested in the first few minutes of myocardial reperfusion. 
Whether the IPost stimulus also exerts remote protection to distant 
organs or tissues or whether it initiates a first and second window of 
protection in a similar manner to IPC is unknown. In common with 
IPC, the current paradigm is that the signaling pathway is initiated 
at the cell membrane surface with the activation of a variety of G-
protein coupled receptors by a number of autacoids (such as adeno-
sine, bradykinin, opioids), the activation of which recruit a wide 
variety of signal transduction pathways many of which appear to 
converge on the mitochondria.  
6.2.1. Cell-surface Receptor Activation 
 The first G-protein coupled receptor (GPCR) to be linked to 
IPost was the adenosine receptor. An experimental study by Yang 
et al in 2005 [203] was the first to observe that the reduction in 
myocardial infarct size elicited by IPost could be abolished in the 
presence of 8-p-(sulfophenyl) theophylline (8-SPT), a non-specific 
adenosine receptor blocker. Interestingly, some 14 years earlier, the 
same research group had been responsible for first implicating 
adenosine receptor activation with the phenomenon of IPC [22]. 
The actual adenosine receptor subtype which is responsible for 
IPost is unclear with studies implicating the adenosine A1 [204], 
A2A [205], and A2B [206] receptor subtypes.  
 A subsequent study by Penna and colleagues [207] has impli-
cated the endogenous activation of the GPCR, bradykinin B2, in 
IPost protection. These authors first demonstrated that two different 
pharmacological antagonists of the bradykinin B2 receptor abol-
ished IPost protection in perfused rat hearts [207]. Finally, the re-
cent finding that mice lacking the bradykinin B2 receptor were 
resistant to IPost protection, provides genetic evidence for the 
obligatory role of endogenous bradykinin B2 receptor activation in 
the setting of IPost [204]. The role for the bradykinin B1 receptor 
was less clear, as the mice were partially protected by the IPost 
stimulus [204].  
 Recently, Zatta and colleagues [208] have linked IPost with the 
endogenous activation of the opioid GPCR. After demonstrating 
that the non-specific opioid receptor antagonist, naloxone, was 
capable of abolishing IPost-protection in the intact rat heart, they 
investigated the effect of IPost in the presence of pharmacological 
antagonists of the ?-, ?-, and ?-opioid receptors [208]. The data 
implicated endogenous stimulation of the ?- and possibly the ?-
opioid receptors in the setting of IPost [208]. In addition, hearts 
subjected to IPost accumulated higher levels of pro-encephalin, 
suggesting perhaps that IPost was capable of increasing endogenous 
opioid content in the reperfused myocardium [208]. Other receptors 
which have been implicated in IPost include the protease activated 
receptor 2 (PAR2) [209] and particulate guanylyl cyclase, the natri-
uretic peptide receptor [210]. 
6.2.2. Signal Transduction Pathways 
 A number of different signalling pathways have been investi-
gated in the setting of IPost. The first of these was the Reperfusion 
Injury Salvage Kinase (RISK) pathway, a group of pro-survival 
protein kinases which on activation at the onset of myocardial 
reperfusion confer powerful cardioprotection [211, 212]. We and 
others have demonstrated that the pharmacological activation of 
components of the RISK pathway such as Akt and Erk1/2 at the 
immediate onset of myocardial reperfusion using a diverse variety 
of agents, which include growth factors, cytokines, GPCR agonists, 
natriuretic peptide, adipocytokines, and ’Statins’ reduce myocardial 
infarct size in the region of 40-50% [211, 212]. Our laboratory and 
others have demonstrated that the cardioprotective benefits of IPost 
are dependent on the activation of Akt and Erk1/2 at the immediate 
onset of myocardial reperfusion [213, 214]. Subsequent studies 
have confirmed the role for Akt and Erk1/2 in the setting of IPost in 
both non-diseased animal hearts and diseased ones [215, 216] as 
well as human atrial muscle [217]. Interestingly, obese mice have 
been reported to be resistant to IPost protection, and this finding 
was associated with insufficient activation of the RISK pathway in 
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the hearts harvested from obese animals compared to control ones 
[218]. This finding underscores the importance of using relevant 
experimental animal models capable of simulating disease patholo-
gies present in patients with coronary heart disease.  
 The Survival Activating Factor Enhancement (SAFE) pathway, 
which comprises the TNF-? receptor and Janus Kinase (JAK)-
Signal transducer and activator of transcription (STAT) pathway, 
has also been linked to cardioprotection elicited by IPost [219, 
220]. Experimental studies have reported that pharmacologically 
inhibiting the JAK-STAT pathway at the onset of myocardial reper-
fusion abrogates the infarct-limiting effects of IPost [219, 220]. 
However, mice with a cardiac-specific STAT3 deletion were found 
to still be amenable to the infarct-limiting effects of IPost, provid-
ing a suitable IPost protocol was used i.e. IPost using 5x5 sec cy-
cles of ischemia/reperfusion reduced myocardial infarct size but 
3x10 sec cycles did not [219]. Using mice with the same cardiac-
restricted STAT-3 deletion, Goodman and colleagues [220] were 
able to demonstrate improved LV function using the IPost protocol 
of 3x10 sec cycles of ischemia/reperfusion, suggesting that STAT-3 
may not be an obligatory mediator of IPost. The mechanism under-
lying the acute form of myocardial protection mediated by the JAK-
STAT pathway is unclear but may relate to as yet unidentified mi-
tochondrial effects [221].  
 Sphingosine kinase (SPK) is a lipid kinase which generates 
sphingosine 1 phosphate (S1P), which in turn regulates cell mitosis, 
apoptosis, cytoskeletal rearrangement, and survival [222]. Jin and 
colleagues [223] have recently demonstrated an obligatory role for 
SPhK1 as a mediator of IPost, which is potentially upstream of the 
RISK pathway. The authors reported that hearts isolated from mice 
lacking SPhK1, sustained larger myocardial infarcts, were resistant 
to IPost, and did not demonstrate activation of the Akt and Erk1/2 
components of the RISK pathway in response to IPost [223].  
 It is well-established that protein kinase C acts as a critical me-
diator of protection in the setting of IPC, providing for the ‘mem-
ory’ elicited by an IPC-stimulus (reviewed in [224]). IPost has been 
reported to also be dependent on PKC activation. Penna and col-
leagues [225] were the first to demonstrate that the non-specific 
PKC inhibitor could abolish the infarct-limiting effects of IPost in 
perfused rat hearts, suggesting that IPost required the activation of 
PKC to confer cardioprotection. A subsequent study by Zatta and 
colleagues [226] has found that IPost-protection could be abolished 
by pharmacological inhibition of the PKC-? isoform in early reper-
fusion. The translocation to the mitochondria of the detrimental 
PKC-?, was reduced in postconditioned hearts. The mechanism 
through which IPost activates PKC is unclear. With respect to the 
cardioprotective effects of PKC, it has been postulated that PKC 
may sensitize the adenosine A2B receptor on the cell surface [206, 
227] and that a special mitochondrial pool of PKC-? confers inhibi-
tion of mitochondrial permeability transition pore (mPTP) opening 
[121].  
 Protein kinase G (PKG) has emerged as a critical mediator of 
cardioprotection in both IPC and IPost (reviewed in [228]). Much 
of the experimental data suggests that in the setting of IPC, it forms 
the final link in the signaling pathway which begins at the plasma 
membrane and terminates at the mitochondria [229]. In the context 
of IPost, its myocardial infarct-limiting effects have been demon-
strated to be sensitive to pharmacological inhibition of the NO-
sGC-cGMP-PKG pathway [203, 230]. Activated PKG at the level 
of the mitochondria is then believed to open the ATP-sensitive 
mitochondrial potassium channel through protein kinase C-? [229]. 
This pathway is presumed to be activated through the Akt compo-
nent of the RISK pathway via eNOS in response to IPost [213]. The 
downstream target of this pathway is believed to be PKC, resulting 
in sensitization of the adenosine A2B receptor [227] or the inhibi-
tion of mPTP opening [231, 232]. 
 
6.2.3. Mitochondria and IPost 
 Many of the signalling pathways underlying IPost appear to 
converge on the mitochondria. In this regard, the mitochondrial 
permeability transition pore (mPTP) has emerged as a critical target 
for cardioprotection in the setting of IPost (reviewed in [233, 234]). 
Preventing its opening at the onset of myocardial reperfusion using 
pharmacological mPTP inhibitors [138, 139, 233] or genetically 
ablating one of its critical components [135, 136, 235], reduces 
myocardial infarct size by 40-50%. IPost [236] has been reported to 
prevent mPTP opening at the onset of myocardial reperfusion, al-
though the mechanism underlying this effect is currently unclear. It 
may involve components of the RISK pathway such as Akt, Erk1/2 
or GSK-3? [237, 238] and/or changes in intracellular pH in the first 
few moments of myocardial reperfusion [76, 77]. Argaud and col-
leagues [236] found that mitochondria isolated from a perfused 
rabbit heart which had been subjected to a standard IPost protocol, 
were more resistant to calcium-induced opening of the mPTP, sug-
gesting that IPost was capable of inhibiting mPTP opening. A sub-
sequent study by the same group, reported that this inhibitory effect 
on mPTP opening was sensitive to pharmacological PI3K inhibi-
tion, suggesting that IPost mediated mPTP inhibition through the 
activation of the PI3K-Akt pathway [237]. We have demonstrated 
that mice lacking cyclophilin-D are resistant to IPost providing 
confirmatory evidence supporting the role of the mPTP in IPost 
[235]. Further studies suggest that the changes in cellular pH in 
early reperfusion of postconditioned hearts may also contribute to 
the inhibition of mPTP opening [77]. 
 In the first few minutes of myocardial reperfusion there is a 
rapid restoration of physiological pH within the cardiomyocyte, 
mediated by the wash-out of lactic acid and the actions of the Na+-
H+ exchanger (NHE) and the Na+-HCO- co-transporter. Interest-
ingly, IPost [76, 77, 239] has been reported to delay the restoration 
of physiological pH in the early moments of myocardial reperfu-
sion. This transient acidosis in the first couple of minutes of reper-
fusion may be sufficient to permit the activation of the RISK path-
way [76], suppress mPTP opening [77], inhibit cardiomyocyte hy-
percontracture, and prevent detrimental calpain activation [239], 
over this critical period of time. The mechanism through which 
IPost modifies cellular pH in early reperfusion is currently unclear, 
but it has been attributed to delayed wash-out of lactate, but another 
potential explanation could be the inhibition of the NHE by the 
RISK pathway, which is activated in IPost-treated hearts. A recent 
study by Avkiran’s laboratory [240] has demonstrated that Akt is 
able to phosphorylate and inhibit the actions of NHE in cardiomyo-
cytes, and so whether this process occurs in postconditioned hearts 
is an interesting possibility. 
 Previous experimental studies have suggested that the ATP-
sensitive mitochondrial potassium (MitoKATP) channel plays a 
pivotal role in IPost, although much of the evidence is circumstan-
tial and based on the use of pharmacological activators and inhibi-
tors of the channel. Studies have demonstrated that the pharmacol-
ogical inhibition of the MitoKATP channel in early reperfusion 
abolished the infarct-limiting effects of IPost [214, 241, 242]. 
 IPost [19] has been reported to reduce the amount of detrimen-
tal ROS generated at the onset of myocardial reperfusion. In con-
trast, ROS may also participate as critical signaling mediators in the 
signal transduction pathway underlying IPost [225]. Penna and 
colleagues [225] were the first to demonstrate that the administra-
tion of the non-specific ROS scavenger, N-acetylcysteine (NAC), 
was able to abrogate the infarct-limiting effect of IPost in perfused 
rat hearts. Crucially, if NAC was administered after the first three 
minutes of myocardial reperfusion had elapsed, no effect on IPost 
was observed, suggesting that ROS signaling during the first couple 
of minutes of myocardial reperfusion was critical to IPost protec-
tion [225]. Subsequent studies using intact rabbit [243] and murine 
[244] hearts have confirmed the involvement of a signaling form of 
ROS in IPost protection.  
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7. EMERGING CONCEPTS IN ISCHEMIC CONDITIONING 
7.1. Combining Different Ischemic Conditioning Stimuli 
 The difference in the ‘timing’ and the ‘site or delivery’ of the 3 
different forms of ischemic conditioning, provide the possibility of 
combining different ischemic conditioning protocols to achieve 
either additive or synergistic cardioprotection. The belief that un-
derlying mechanisms may be similar across the three forms of 
ischemic conditioning and the limitations of the current animal 
models of IRI in terms of resolution of cardioprotection may also 
have contributed to the lack of enthusiasm for combining different 
protocols. IPC has been tried in combination with IPost by several 
investigators with inconclusive findings [213, 245, 246]. Recent 
experimental studies have combined RIPerC with IPost protocols 
and observed additive cardioprotection, although no additive effect 
was observed when combined with IPC [247]. Further investigation 
is now required to explore the possibility of combining ischemic 
conditioning protocols in the clinical setting. 
7.2. Gene Therapy for Cardioprotection 
 The identification of iNOS as a distal mediator of delayed car-
dioprotection has been investigated as a therapeutic strategy using 
gene therapy to adenovirally transfect adult murine hearts with 
iNOS, a strategy which resulted in infarct-size limitation, through a 
mechanism involving COX-2 [248]. Similar findings have been 
reported with Ec-SOD adenoviral transfection [249, 250]. The same 
authors are exploring the possibility of adenoviral transfection of 
other known distal mediators (such as COX-2) of delayed cardio-
protection as a strategy for long-term ‘prophylactic cardioprotec-
tion’ in animal models (reviewed in [251]). The possibility of main-
taining the heart in a state of cardioprotection is particularly attrac-
tive given the unpredictable onset of acute coronary syndromes. 
However, the long-term consequences of prolonged activation of 
cardioprotective mediators such as iNOS and COX-2 would have to 
be investigated. In this regard, Li et al [252, 253] have demon-
strated that adenoviral transfection of murine hearts with heme 
oxygenase-1 or iNOS resulted in long-term cardioprotection with 
MI size reduction at one year with no adverse functional effects.  
7.3. Regenerative Therapy for Cardioprotection 
 Regenerative therapy using stem cells as a treatment strategy 
for coronary heart disease remains an ongoing area of research 
interest and has been recently been investigated in the setting IPC in 
two areas. In the first area, IPC has been used as a therapeutic strat-
egy for improving survival and engraftment of bone marrow de-
rived stem cells [254]. The second area the focus has been on the 
potential role of bone marrow derived stem cells as ‘mediators’ of 
delayed IPC. Li and co-workers [255] found using an in vivo mur-
ine model that a standard IPC stimulus could recruit into the myo-
cardium bone marrow-derived endothelial progenitor cells (EPC) 
within 3 hours, and that these cells ‘imported’ cardioprotective 
mediators such as iNOS and eNOS into the ischemic myocardium. 
In human volunteers, repeated episodes over one month of remote 
ischemic preconditioning induced by brief cycles of ischemia and 
reperfusion of the arm, has been reported to be associated with an 
increase in circulating EPC’s and improved endothelial function 
[256], but the contribution of the EPC’s to these beneficial endothe-
lial effects are unclear. In a subsequent study, Kamota and co-
workers [257] demonstrated using an in vivo murine model that IPC 
induced by brief cycles of occlusion and reperfusion of the aorta 
(remote preconditioning stimulus) had several beneficial effects 24 
hours later including reduced myocardial infarct size, preserved LV 
ejection fraction, augmented peripheral circulating levels of CD34+ 
and flk-1+ bone marrow stem cells (BMSC), increased myocardial 
targeting to the ischemic risk zone of GFP-tagged BMSC. The IPC 
stimulus was reported to increase levels of serum vascular endothe-
lial growth factor and stromal cell-derived factor-1? [257]. Cru-
cially, using antibodies to abrogate the IPC-induced elevation and 
targeting of BMSC, also abolished the cardioprotective benefit. 
Clearly, the mechanism underlying the cardioprotective benefits of 
BMSC are unclear but over a relatively short time interval (24 
hours) [257], the release of cardioprotective humoral factors by 
BMSC into the infarcted myocardium would seem a possible ex-
planation.  
7.4. Neural Pathways in Cardioprotection 
 It has been suggested that neural pathways are involved in me-
diating the cardioprotective stimulus from the remote conditioned 
organ or tissue to the target organ or tissue in the setting of RIC [7]. 
Whether neural pathways are also involved in IPC is an interesting 
unanswered question. Kudej and co-workers [258] demonstrated 
that regional cardiac denervation of the porcine heart abrogated the 
in vivo infarct-limitation provided by delayed IPC and prevented 
the upregulation of myocardial iNOS and COX-2, established me-
diators of delayed cardioprotection. However, the cardioprotection 
elicited by early IPC was not affected [258]. Whether cardiac in-
nervation is required during the IPC stimulus or at the time of myo-
cardial infarction is unclear. Clearly, further work needs to be un-
dertaken to examine the role cardiac nerves contribute to delayed 
IPC. In this respect, hearts excised from remote limb precondi-
tioned rats generated smaller infarcts on the Langendorff-apparatus 
[169], suggesting that cardiac innervation at the time of infarction 
may not be necessary for cardioprotection, presumably because the 
heart was already in a preconditioned state.  
7.5. MicroRNAs and Cardioprotection 
 MicroRNAs (miRNAs) are noncoding RNAs involved in the 
post-transcriptional regulation of protein expression, which have 
been recently implicated in cardiac development, cardiac hypertro-
phy, cardiac failure and arrhythmogenesis (reviewed in [259]). It 
has been demonstrated that miRNA’s may contribute to classical 
IPC cardioprotection [260]. Yin and co-workers [261] initially 
demonstrated that heat stress of mice increased peripheral circulat-
ing levels of miRNA’s 1, 21, and 24, which when isolated and in-
jected into naïve mice conferred cardioprotection 24 hours later in 
Langendorff-perfused hearts. A subsequent study by the same 
groups found a similar serum miRNA profile produced in response 
to a standard IPC [262]. In this case, the isolated and purified 
miRNA were injected into the LV wall and resulting in infarct size 
limitation 48 hours later, a finding which was associated with 
upregulation of eNOS, HSP70, and the HSP70 transcription factor 
(HSF-1) [262], known mediators of delayed cardioprotection. 
Clearly, further work is required to determine how the IPC stimulus 
generates miRNA and which proteins or kinases are modified by 
miRNA in the context of delayed IPC. Another intriguing possibil-
ity is whether miRNA could act as the humoral factor(s) conveying 
cardioprotection from the distal remote preconditioned organ or 
tissue to the heart. 
8. CONCLUSION 
 The phenomenon of ischemic preconditioning has evolved into 
a number of different forms including remote ischemic conditioning 
and ischemic postconditioning, a process which has facilitated its 
translation into the clinical setting of cardioprotection. Ongoing 
experimental studies continue to elucidate the mechanisms underly-
ing these 3 different forms of endogenous cardioprotection and over 
the years huge progress has been made towards the understanding 
of adaptation of the cardiomyocyte to ischemia-reperfusion injury 
and the intracellular signal transduction pathways that mediate this 
process. Proof-of-concept clinical studies have demonstrated bene-
ficial effects with ischemic preconditioning, ischemic postcondi-
tioning and remote ischemic conditioning in a variety of clinical 
settings and reviewed in another article in this special issue. There-
fore, harnessing the powerful cardioprotection elicited by ischemic 
preconditioning, remote ischemic conditioning, and ischemic post-
conditioning could one day provide a therapeutic strategy for pro-
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tecting the heart against acute IRI, preserving cardiac function and 
improving clinical outcomes in patients with ischemic heart disease. 
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